Gene Editing Tools & Services

Gene Editing Proof of Concept and Beyond in <6 Months

Therapeutic teams shouldn't have to build broad gene editing capability internally just to answer whether an edit is feasible for their target. ElevateBio offers three defined paths with known deliverables, predictable timelines, and a straightforward IP approach, so programs move forward on evidence, not optimism.

The Early Challenge

Building broad gene editing capability internally is resource-intensive and time-consuming. Traditional partnerships add complexity rather than clarity.

- Significant upfront capital required before meaningful data
- Complex royalty obligations stacked across multiple technology licenses
- Long-term, ill-defined contracts with large milestone commitments
- Difficulty accessing the breadth of modalities needed to find the right edit

The ElevateBio Approach

ElevateBio provides a direct path to the answers your program needs, without the resource burden of building that capability internally.

- Go/no-go feasibility data typically in under 6 months
- Standard terms and a fixed scope mean less negotiation and a faster start
- Centralized ownership, streamlined licensing: wholly owned components providing a straightforward path to accessing our technology
- Five editing modalities and versatile AI tools to find the right approach for your target

Demonstrated
success generating potent, specific editors

<6 months
to feasibility data and go/no-go decision*

5 editing modalities
nuclease, base, RT, insertion & epigenetic

Increase
the probability of clinical success for your therapeutic program

Three Paths To Therapeutic Progress

Match the model to where your program is.

Getting to a gene editing decision has been harder than it needs to be. ElevateBio built these three models around the decisions therapeutic teams face.

Proof of Concept*
Under 6 months

Prove the edit works.

Answer whether gene editing is viable for your target before committing significant internal resources. Standard terms, fixed deliverable, no long-term obligation. Start in weeks, not months of contract negotiation.

Deliverable: *Up to 3 gene editors for your target + feasibility & initial safety data*

Clinical Candidate
~18 months or less*

Refine the potency and specificity of your candidate and maximize the likelihood of clinical success.

For teams progressing from a completed Proof of Concept, or ready to commit to a full development arc from the start. A **single engagement** takes a clinical candidate through optimization, *in vivo* validation, and IND-supporting characterization.

Deliverable: *Clinical-ready editor + IND-supporting data*

Pipeline Model
Timeline by agreement

Build a differentiated gene editing pipeline.

Full collaboration applying our entire suite of tools and scientific expertise to your R&D efforts, allowing you to pursue **multiple targets** in parallel.

Deliverable: *Scope and targets defined by agreement*

"**We operate as an extension of your team.** Visibility and transparency are critical to the success of a partnership."

That means shared oversight on candidate selection, access to ElevateBio scientists throughout, with an option to hand off to cGMP manufacturing when programs are ready.

Partnership Model Comparison

Which Path Is Right for Your Program?

Many programs start at Proof of Concept. Others are ready to commit to a full Clinical Candidate arc from the start. A few are ready for a full pipeline collaboration. Use this comparison to find where you fit.

	PROOF OF CONCEPT*	CLINICAL CANDIDATE	PIPELINE MODEL
Primary Purpose	Prove the edit works	Advance candidates toward clinic	Build and scale pipelines
Best Fit For	Early program evaluation	IND-bound programs	Multi-asset organizations
Target Scope	Single target	Single target	Multiple targets
Problem Addressed	Edit feasibility	Refine potency and specificity	Portfolio scale and differentiation
Data Generated	Feasibility and initial safety	In vitro, In vivo and IND-supporting	Program- and portfolio-level
Timeframe	<6 months	18 months or less*	Varies based on scope
Decision Enabled	Go / no-go on edit	Advance toward IND	Pipeline-level commitment
Deliverable	**Up to 3 editors + feasibility & initial safety data**	**Clinical-ready editor + IND-supporting data**	**Clinical-ready editors for multiple targets**

Start Here

The Proof of Concept model is the easiest first step.

- Standard terms with a fixed deliverable.
- Limited contract negotiation means a faster start.
- Results in hand in under 6 months.
- No long-term commitment; stand-alone by design.
- Progress to Clinical Candidate model or stop. You decide, based on the data.

Take The First Step

The fastest way to know if gene editing will work for your program is to start.

A Proof of Concept engagement delivers clarity quickly, on standard terms with a fixed deliverable and no long-term obligation.

Why ElevateBio

Speed & Predictability

Five editing modalities and AI-driven discovery deliver potent and specific editors, with results on a predictable timeline.

Integrated IP Strategy

Centralized ownership, streamlined licensing: wholly owned components providing a straightforward path to accessing our technology.

Integrated Manufacturing

Our gene editing tools are developed with cGMP manufacturing compatibility in mind — so when your program is ready, the transition to ElevateBio manufacturing is straightforward.

Collaborative Excellence

Transparency, collaborative problem-solving, and high-quality data packages designed to support key decisions and regulatory filings.

Start the Conversation →

ELEVATE.BIO

Explore All Gene Editing Services

elevate.bio/manufacturing-discovery-services/gene-editing-design-optimization/

partnerships@elevate.bio

*Excludes targeted insertion programs.